Publications related to History of cancer chemotherapy

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Freddy Radtke, Nadine Fournier, Etienne Meylan, Justine Pascual, Amber Dawn Bowler, Anita Bodac, Vincent Roh

Elevated peripheral blood and tumor-infiltrating neutrophils are often associated with a poor patient prognosis. However, therapeutic strategies to target these cells are difficult to implement due to the life-threatening risk of neutropenia. In a genetica ...

Springernature2024

Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma

Paul Joseph Dyson, Valentin Simeonov, Fabien Kuttler, Irina Sinenko, Patrik Aouad

Retinoblastoma is the most common pediatric eye cancer. It is currently treated with a limited number of drugs, adapted from other pediatric cancer treatments. Drug toxicity and relapse of the disease warrant new therapeutic strategies for these young pati ...

WILEY2023

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Matthias Lütolf, Michele De Palma, Mauro Delorenzi, Mario Leonardo Squadrito, Sina Nassiri, Nikolche Gjorevski, Simone Ragusa, Alan Nicolas Thierry Guichard, Borja Prat Luri, Laureline Wetterwald

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential respon ...

2020

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Paul Joseph Dyson, Rosario Scopelliti, Felix Daniel Bobbink, Patrycja Nowak-Sliwinska, Anna Katherine Renfrew

Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the dev ...

WILEY-V C H VERLAG GMBH2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Paul Joseph Dyson, Gerardo Turcatti, Fabien Kuttler, Damiano Banfi, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Mauro Delorenzi, Yu-Ting Huang

Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due ...

Springer2019

Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration

Gianrocco Lazzari, Agata Mlynska

The management of advanced ovarian cancer is challenging due to the high frequency of recurrence, often associated with the development of resistance to platinum-based chemotherapy. Molecular analyses revealed the complexity of ovarian cancer with particul ...

SPANDIDOS PUBL LTD2019

A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1

Paul Joseph Dyson, Laure Menin, Wee Han Ang

Cisplatin [cis-diamminedichloroplatinum(II) (cis-DDP)] is one of the most successful anticancer agents effective against a wide range of solid tumors. However, its use is restricted by side effects and/or by intrinsic or acquired drug resistance. Here, we ...

PNAS2019

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Mauro Delorenzi, Delphine Yvette L Grun

Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients wi ...

AMER SOC CLINICAL INVESTIGATION INC2019

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

History of cancer chemotherapy

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration

A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Graph Chatbot

Chat with Graph Search

Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth

Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma

Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation

Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration